{"id":54281,"date":"2026-01-15T22:42:39","date_gmt":"2026-01-15T14:42:39","guid":{"rendered":"https:\/\/flcube.com\/?p=54281"},"modified":"2026-01-15T22:42:40","modified_gmt":"2026-01-15T14:42:40","slug":"fresenius-kabi-licenses-tq-therapeutics-cell-tech-for-automated-t-cell-isolation-in-cell-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54281","title":{"rendered":"Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy"},"content":{"rendered":"\n<p><strong>Fresenius Kabi<\/strong> and <strong>TQ Therapeutics<\/strong> announced a strategic\u2011development agreement granting Fresenius Kabi <strong>exclusive rights<\/strong> to develop, manufacture, and distribute products incorporating TQ Therapeutics&#8217; proprietary <strong>cell selection technology<\/strong> into its <strong>Cue Cell Processing System<\/strong> for cell and gene therapy applications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Fresenius Kabi (licensee) and TQ Therapeutics (licensor)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Strategic\u2011development and exclusive license<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>TQ Therapeutics&#8217; affinity and column\u2011based cell isolation technology<\/td><\/tr><tr><td><strong>Integration<\/strong><\/td><td>Cue Cell Processing System (Fresenius Kabi)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>T\u2011cell isolation from whole blood and apheresis products<\/td><\/tr><tr><td><strong>Processing Time<\/strong><\/td><td>&lt;2 hours<\/td><\/tr><tr><td><strong>Goal<\/strong><\/td><td>Automated, robust, high\u2011purity T\u2011cell production for cell\/gene therapy manufacturing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile\">Technology Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Affinity and column\u2011based cell isolation<\/strong> technology enables selective capture of T cells from complex biological samples<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Integration with <strong>Cue Cell Processing System<\/strong> creates a <strong>closed, automated workflow<\/strong> reducing manual processing and contamination risk<\/li>\n\n\n\n<li><strong>Performance:<\/strong> Achieves <strong>high purity T\u2011cell isolation<\/strong> in less than two hours, significantly faster than conventional methods (4\u20116 hours)<\/li>\n\n\n\n<li><strong>Impact:<\/strong> Helps therapeutic developers <strong>work more efficiently<\/strong> and <strong>potentially accelerate time\u2011to\u2011market<\/strong> for cell and gene therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-landscape\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Cell Therapy Manufacturing Market<\/strong><\/td><td>$3.5\u202fbillion<\/td><td>$5.2\u202fbillion<\/td><td>$7.8\u202fbillion<\/td><\/tr><tr><td><strong>T\u2011Cell Isolation Submarket<\/strong><\/td><td>$420\u202fmillion<\/td><td>$680\u202fmillion<\/td><td>$1.05\u202fbillion<\/td><\/tr><tr><td><strong>Automated Systems Penetration<\/strong><\/td><td>35\u202f%<\/td><td>48\u202f%<\/td><td>62\u202f%<\/td><\/tr><tr><td><strong>Fresenius Kabi Market Share Target<\/strong><\/td><td>12\u202f%<\/td><td>18\u202f%<\/td><td>25\u202f%<\/td><\/tr><tr><td><strong>Revenue Contribution (USD)<\/strong><\/td><td>$50\u202fmillion<\/td><td>$122\u202fmillion<\/td><td>$262\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Miltenyi Biotec<\/strong> \u2013 CliniMACS\u00ae system (market leader, 40\u202f% share)<\/li>\n\n\n\n<li><strong>Thermo Fisher<\/strong> \u2013 CTS\u2122 Dynabeads\u2122 (25\u202f% share)<\/li>\n\n\n\n<li><strong>Lonza<\/strong> \u2013 Cocoon\u00ae Platform (15\u202f% share)<\/li>\n\n\n\n<li><strong>Fresenius Kabi + TQ<\/strong> \u2013 <strong>First integrated system<\/strong> with &lt;2\u2011hour processing time<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Fresenius Kabi will leverage its <strong>global GMP manufacturing footprint<\/strong> to commercialize the integrated system by <strong>Q4\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Client Base:<\/strong> Targets <strong>200+ cell\/gene therapy developers<\/strong> globally, including CAR\u2011T and TCR\u2011T companies<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> System designed to meet <strong>FDA, EMA, and NMPA<\/strong> requirements for cell therapy manufacturing<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> <strong>Prototype validation<\/strong> completed; <strong>clinical beta testing<\/strong> with 5 partners initiated in <strong>Q1\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding technology integration timelines, market penetration, and revenue forecasts. Actual results may differ due to technical challenges, competitive responses, and regulatory approval timelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fresenius Kabi and TQ Therapeutics announced a strategic\u2011development agreement granting Fresenius Kabi exclusive rights to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,660,4555],"class_list":["post-54281","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cell-therapy","tag-fresenius-kabi","tag-tq-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fresenius Kabi and TQ Therapeutics announced a strategic\u2011development agreement granting Fresenius Kabi exclusive rights to develop, manufacture, and distribute products incorporating TQ Therapeutics&#039; proprietary cell selection technology into its Cue Cell Processing System for cell and gene therapy applications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54281\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy\" \/>\n<meta property=\"og:description\" content=\"Fresenius Kabi and TQ Therapeutics announced a strategic\u2011development agreement granting Fresenius Kabi exclusive rights to develop, manufacture, and distribute products incorporating TQ Therapeutics&#039; proprietary cell selection technology into its Cue Cell Processing System for cell and gene therapy applications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54281\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T14:42:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-15T14:42:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54281#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54281\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy\",\"datePublished\":\"2026-01-15T14:42:39+00:00\",\"dateModified\":\"2026-01-15T14:42:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54281\"},\"wordCount\":357,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cell-therapy\",\"Fresenius Kabi\",\"TQ Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54281#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54281\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54281\",\"name\":\"Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-15T14:42:39+00:00\",\"dateModified\":\"2026-01-15T14:42:40+00:00\",\"description\":\"Fresenius Kabi and TQ Therapeutics announced a strategic\u2011development agreement granting Fresenius Kabi exclusive rights to develop, manufacture, and distribute products incorporating TQ Therapeutics' proprietary cell selection technology into its Cue Cell Processing System for cell and gene therapy applications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54281#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54281\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54281#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Fresenius Kabi and TQ Therapeutics announced a strategic\u2011development agreement granting Fresenius Kabi exclusive rights to develop, manufacture, and distribute products incorporating TQ Therapeutics' proprietary cell selection technology into its Cue Cell Processing System for cell and gene therapy applications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54281","og_locale":"en_US","og_type":"article","og_title":"Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy","og_description":"Fresenius Kabi and TQ Therapeutics announced a strategic\u2011development agreement granting Fresenius Kabi exclusive rights to develop, manufacture, and distribute products incorporating TQ Therapeutics' proprietary cell selection technology into its Cue Cell Processing System for cell and gene therapy applications.","og_url":"https:\/\/flcube.com\/?p=54281","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-15T14:42:39+00:00","article_modified_time":"2026-01-15T14:42:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54281#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54281"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy","datePublished":"2026-01-15T14:42:39+00:00","dateModified":"2026-01-15T14:42:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54281"},"wordCount":357,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cell-therapy","Fresenius Kabi","TQ Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54281#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54281","url":"https:\/\/flcube.com\/?p=54281","name":"Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-15T14:42:39+00:00","dateModified":"2026-01-15T14:42:40+00:00","description":"Fresenius Kabi and TQ Therapeutics announced a strategic\u2011development agreement granting Fresenius Kabi exclusive rights to develop, manufacture, and distribute products incorporating TQ Therapeutics' proprietary cell selection technology into its Cue Cell Processing System for cell and gene therapy applications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54281#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54281"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54281#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T\u2011Cell Isolation in Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54281"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54281\/revisions"}],"predecessor-version":[{"id":54283,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54281\/revisions\/54283"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}